Valuation: NetraMark Holdings Inc.

Market Cap 64.35M 45.93M 40.05M 37.82M 34.34M 4.41B 64.62M 453M 175M 2.24B 173M 169M 7.21B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 64.35M 45.93M 40.05M 37.82M 34.34M 4.41B 64.62M 453M 175M 2.24B 173M 169M 7.21B EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
89.23%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-15 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-08 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 45.93M
-0.80%-0.37%-2.89%+50.06% 3,667B
+0.79%+6.22%+0.38%+1,049.03% 427B
-2.58%+3.94%+68.06%+143.30% 82.56B
+0.76%-2.24%-22.47%+19.45% 77.91B
+1.00%-3.12%-19.82%-16.31% 73.77B
+0.51%-4.19%-46.58%+165.91% 62.34B
-0.26%+6.86%+13.20%-6.28% 48.62B
-2.45%-4.65%-17.73%+45.37% 38.42B
-0.97%+7.25%+124.99%+300.66% 37.45B
Average -0.60%+1.24%+10.79%+194.58% 501.61B
Weighted average by Cap. +0.08%+1.48%-1.39%+147.64%

Financials

2026 *2027 *
Net sales 401K 286K 250K 236K 214K 27.46M 403K 2.82M 1.09M 13.96M 1.08M 1.05M 44.93M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!